Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)

Prospective, open label, multicenter randomized clinical trial

Inclusion criteria

• Over 19 years old
• Chronic Renal Failure Stage IIIb, IV, V (CKD-EPI eGFR <45 / <30 / <15 or dialysis)
• Patients treated with a new generation drug eluting stent.
• Patients who signed consent form

Exclusion criteria

• Over 85 years old
• Patients with high risk of bleeding 1) History of hemorrhagic stroke 2) Stroke, dementia or central nervous system damage within 1 year 3) Head trauma or brain surgery within 6 months 4) Tumor in the skull 5) If aortic dissection is suspected 6) Internal bleeding within 6 weeks 7) In case of active bleeding or bleeding disorder 8) In case of major surgery, trauma or bleeding within 3 weeks
• Patients who need oral anticoagulant
• Pregnant women or women of childbearing age
• Life expectancy is less than 1 year
• Patients with a history of intracranial bleeding
• Moderate to severe hepatic impairment (Child-Pugh class B or C)